SMS Lifesciences India Limited

SMSLIFE

INE320X01016

Pharmaceuticals

End-of-day quote NSE India S.E. Other stock markets 03:30:00 19/06/2024 am IST			5-day change	1st Jan Change
797 ^INR	-1.31%		-1.64%	+50.50%

27/05	SMS Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI
10/02	SMS Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

SMS Lifesciences India Limited Recommends Dividend for the Financial Year 2022

May 28, 2022 at 03:52 pm IST

SMS Lifesciences India Limited board of directors has recommended a dividend of INR 1.50 (15%) per equity share INR 10.0 face value, for the year 2022, subject to the approval of the shareholders at the upcoming 16th annual general meeting (AGM) of the company.

Latest news about SMS Lifesciences India Limited

SMS Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	27/05	CI
SMS Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	10/02	CI
SMS Lifesciences India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11/11	CI
SMS Lifesciences India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/23/08	CI
SMS Lifesciences India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	29/23/29	CI
SMS Lifesciences India Limited Announces Resignation of Venkafasubbarao Polluri as Independent Director from the Board and Member of Audit Committee	10/23/10	CI
SMS Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/23/10	CI
CARE Affirms BBB+ Rating on SMS Lifesciences' Long-term Bank Financing; Outlook Stable	30/22/30	MT
SMS Lifesciences India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
SMS Lifesciences India Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	09/22/09	CI
SMS Life Sciences Telangana, India Unit Gets Establishment Inspection Report from US FDA	24/22/24	MT
SMS Lifesciences India Limited Reports Earnings Results for the Full Year Ended March 31, 2022	28/22/28	CI
SMS Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	28/22/28	CI
US FDA Clears SMS Lifesciences' Manufacturing Plant in Kazipally, India	11/22/11	MT
SMS Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	11/22/11	CI
Chemwerth, Inc. acquired 10% stake in Mahi Drugs Private Limited from SMS Lifesciences India Limited.	30/21/30	CI
SMS Lifesciences India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	13/21/13	CI
SMS Lifesciences India Limited Announces Executive Changes	13/21/13	CI
Sms Lifesciences India Limited Announces Neelaveni Thummala as Resignation of Independent Director, Date of Cessation September 2, 2021	02/21/02	CI
SMS Lifesciences India Limited Reports Unaudited Standalone and Consolidated Earnings Results for the First Quarter Ended June 30, 2021	14/21/14	CI
SMS Lifesciences India Limited Announces Consolidated and Standalone Earnings Results for the First Quarter Ended June 30, 2021	13/21/13	CI
SMS Lifesciences India Limited Announces Resignation of Ramesh Babu Potluri from the Position of Non-Executive Director	19/21/19	CI
SMS Lifesciences India Limited Announces Audited Standalone and Consolidated Earnings Result for the Fourth Quarter and Year Ended March 31, 2021	18/21/18	CI
Sms Lifesciences India Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/21/12	CI
SMS Lifesciences India Limited Announces Standalone and Consolidated Earnings Result for the Year Ended March 31, 2020	08/20/08	CI

Chart SMS Lifesciences India Limited

Duration

Period

More charts

Company Profile

SMS Lifesciences India Limited is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph.Eur / IP, Famotidine USP / Ph.Eur / IP, Sildenafil Citrate USP / Ph.Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph.Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private limited.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SMS LIFESCIENCES INDIA LIMITED	+50.50%	29.29M
ELI LILLY AND COMPANY	+52.93%	803B
NOVO NORDISK A/S	+40.98%	629B
JOHNSON & JOHNSON	-7.08%	351B
MERCK & CO., INC.	+17.40%	324B
ABBVIE INC.	+10.58%	303B
ASTRAZENECA PLC	+16.42%	244B
ROCHE HOLDING AG	+2.17%	226B
NOVARTIS AG	+10.66%	215B
AMGEN INC.	+6.24%	164B